Showing 7141-7150 of 8649 results for "".
- New Penn Study Finds Promising Model for Restoring Cone Functionhttps://modernod.com/news/new-penn-study-finds-promising-model-for-restoring-cone-function/2482111/Vision scientists from the Division of Experimental Retinal Therapies at the University of Pennsylvania School of Veterinary Medicine used functional magnetic resonance imaging (fMRI) to assess brain responses to lights that stimulate only cone cells in dogs with naturally occurrin
- FDA Warns Consumers of Contaminated Copycat Versions of Lumify Eye Dropshttps://modernod.com/news/fda-warns-consumers-of-contaminated-copycat-versions-of-lumify-eye-drops/2482094/FDA is warning consumers not to purchase or use South Moon, Rebright, or FivFivGo eye drops because of the potential risk of eye infection. These are copycat eye drops that consumers can easily mistake for Bausch + Lomb’s Lumify brand eye drops, an over-the-counter product approved for
- Opthea Names New Clinical and Regulatory Leadership Membershttps://modernod.com/news/opthea-names-new-clinical-and-regulatory-leadership-members/2482091/Opthea announced the appointment of Julie Clark, MD, MS, as Senior Vice President (SVP), Clinical Development; and Fang Li, PhD, RAC, as SVP, Regulatory Affairs, effective February 1, 2024. Dr. Clark and Dr. Li will report to Opthea Chief Executive Officer Frederic Guerard, PharmD,
- New Long-Term Data for Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)https://modernod.com/news/new-long-term-data-for-genentechs-vabysmo-show-sustained-retinal-drying-and-vision-improvements-in-retinal-vein-occlusion-rvo/2482090/Genentech announced new 72-week data from two global phase 3 studies, BALATON and COMINO, evaluating Vabysmo (faricimab-svoa) in macular edema due to branch and central retinal vein occlusion (BRVO and CRVO). The data showed nearly 60% of people receiving Vabysmo in BALATON and up to 48
- Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis Pigmentosahttps://modernod.com/news/nanoscope-therapeutics-provides-regulatory-update-on-mco-010-for-the-treatment-of-retinitis-pigmentosa/2482078/Nanoscope Therapeutics provided an update following recent regulatory discussions with the FDA and from the scientific advice meeting with the Icelandic Medicines Agency (IMA), regarding the regulatory path of MCO-010 for the treatment of retinitis pigmentosa (RP). In connection wi
- Coherus Divest Ophthalmology Franchise to Sandoz in $170 Million Dealhttps://modernod.com/news/coherus-divest-ophthalmology-franchise-to-sandoz-in-170-million-deal/2482075/In a move to pay down debt and focus on its oncology business, Coherus BioSciences has entered into an agreement to divest its Cimerli (ranibizumab-eqrn) ophthalmology franchise to Sandoz for $170 million in cash, plus Cimerli inventory costs. This divestiture includes Co
- EyePoint Begins Phase 2 VERONA Clinical Trial of EYP-1901 to Treat Diabetic Macular Edemahttps://modernod.com/news/eyepoint-begins-phase-2-verona-clinical-trial-of-eyp-1901-to-treat-diabetic-macular-edema/2482049/EyePoint Pharmaceuticals, a company focused on therapeutics for retinal diseases, announced that the first patient has been dosed in the VERONA clinical trial of the company’s EYP-1901 for diabetic macular edema (DME). EYP-1901 is an investigational sustained delivery therapy containing vor
- Study Indicates a Potential Treatment for Corneal Endothelial Disease, Reducing the Need for Corneal Transplantshttps://modernod.com/news/study-indicates-a-potential-treatment-for-corneal-endothelial-disease-reducing-the-need-for-corneal-transplants/2482045/Findings from a study in The American Journal of Pathology, published by Elsevier, reveal that administration of the neuropeptide α-melanocyte–stimulating hormone (&al
- Regeneron Wins Patent Case to Extend Eylea Protectionhttps://modernod.com/news/regeneron-wins-patent-case-to-extend-eylea-protection/2482035/A West Virginia judge ruled that Viatris' proposed biosimilar violates a Regeneron patent that covers ophthalmic formulations of Eylea, according to news reports. The patent is expected to expire in June 2027.
- Cellusion Receives FDA Orphan Drug Designation for CLS001https://modernod.com/news/cellusion-receives-fda-orphan-drug-designation-for-cls001/2482028/Cellusion announced that the FDA has granted orphan drug designation to its regenerative medicine product, “iPS cell-derived corneal endothelial cell substitute,” (CLS001) for the treatment of bullous keratopathy. FDA grants orphan drug designation if the drug